{"prompt": "['Product: MK-3475', '20', 'Protocol/Amendment No.: 604-09', '3.0 OBJECTIVE(S) & HYPOTHESIS(ES)', 'To accomplish the objectives listed below, pembrolizumab + EP will be compared with', 'placebo + EP for the treatment of subjects with newly diagnosed ES-SCLC.', '3.1', 'Primary Objective(s) & Hypothesis(es)', '1) Objective: To evaluate PFS as assessed by BICR per RECIST 1.1 modified to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.', 'Hypothesis (H1): Pembrolizumab + EP prolongs PFS per RECIST 1.1 by BICR', 'compared with placebo + EP.', '2) Objective: To evaluate OS.', 'Hypothesis (H2): Pembrolizumab + EP prolongs os compared with placebo + EP.', 'The study is considered to have met its objective if the pembrolizumab + EP arm is superior', 'to placebo + EP in PFS or OS.', '3.2', 'Secondary Objective(s) & Hypothesis(es)', '1) Objective: To evaluate ORR as assessed by BICR per RECIST 1.1 modified to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.', 'Hypothesis: Pembrolizumab + EP improves ORR per RECIST 1.1 by BICR', 'compared to placebo + EP.', '2) Objective: To evaluate DOR as assessed by BICR per RECIST 1.1 modified to', 'follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.', '3) Objective: To evaluate the safety profile in each treatment arm using NCI CTCAE', '4.0.', '4) Objective: To evaluate the following patient-reported outcomes (PROs):', 'Mean change from baseline at Week 18 in global health status/quality of life', 'using the European Organization for Research and Treatment of Cancer (EORTC)', 'Quality of Life Questionnaire Core 30 (QLQ-C30) global health status/quality of', 'life scale. If the overall PRO completion or compliance rates at Week 18 are less', 'than 60% or 80%, respectively, then the primary analysis time point will be', 'moved to the next earliest time point in which the rates are at least 60% for', 'completion and at least 80% for compliance.', 'Time to true deterioration in the composite endpoint of cough, chest pain, and', 'dyspnea using the EORTC QLQ-C30 and Lung Cancer Module 13 (QLQ-LC13).', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']['Product: MK-3475', '21', 'Protocol/Amendment No.: 604-09', '3.3', 'Exploratory Objectives', '1) Objective: To evaluate changes in health-related quality of life assessments from', 'baseline using the EORTC QLQ-C30 and EORTC QLQ-LC13.', '2) Objective: To characterize utilities using the European Quality of Life', 'Five-dimension Five-level Scale Questionnaire (EQ-5D-5L).', '3) Objective: To evaluate ORR, PFS, and DOR per irRECIST as assessed by the', 'investigator.', '4) Objective: To evaluate ORR and PFS as assessed by BICR per RECIST 1.1 modified', 'to follow a maximum of 10 target lesions and a maximum of 5 target lesions per', 'organ, and os by PD-L1 expression (tumor proportion score [TPS] <1% versus 1%,', 'combined positive score [CPS] <1 versus', '1).', '5) Objective: To evaluate the relationship between deoxyribonucleic acid (DNA)', 'mutational burden and ribonucleic acid (RNA) immune signatures analyses and', 'clinical outcome.', '6) Objective: To identify molecular (genomic, metabolic and/or proteomic) biomarkers', 'that may be indicative of clinical response/resistance, safety, pharmacodynamic', 'activity, and/or the mechanism of action of pembrolizumab + EP.', '4.0 BACKGROUND & RATIONALE', '4.1 Background', \"Refer to the Investigator's Brochure (IB)/approved labeling for detailed background\", 'information on MK-3475.', '4.1.1 Pharmaceutical and Therapeutic Background', 'The importance of intact immune surveillance in controlling outgrowth of neoplastic', 'transformation has been known for decades [1]. Accumulating evidence shows a correlation', 'between tumor-infiltrating lymphocytes (TILs) in cancer tissue and favorable prognosis in', 'various malignancies [2] [3] [4] 5 6 [7] [8 [9] [10] [11] [12] [13] [14] [15] [16] [17] [18]', '[19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37]. In', 'particular, the presence of CD8+ T cells and the ratio of CD8+ effector T-cells to FoxP3+', 'regulatory T-cells seems to correlate with improved prognosis and long-term survival in solid', 'malignancies such as ovarian, colorectal, and pancreatic cancer, hepatocellular carcinoma,', 'malignant melanoma and renal cell carcinoma. Tumor-infiltrating lymphocytes can be', 'expanded ex vivo and re infused, inducing durable objective tumor responses in cancers such', 'as melanoma [38] [39].', 'The programmed cell death protein-1 (PD-1) receptor-ligand interaction is a major pathway', 'hijacked by tumors to suppress immune control. The normal function of PD-1, expressed on', 'MK-3475-604-09 Final Protocol', '23-Apr-2019', 'Confidential']\n\n###\n\n", "completion": "END"}